Advertisement
Advertisement

LRMR

LRMR logo

Larimar Therapeutics Inc

4.27
USD
-0.05
-1.16%
Dec 18, 14:02 UTC -5
Open

Larimar Therapeutics Inc Profile

About

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

Info & Links

CEO

Carole S. Ben-Maimon

Headquarters

THREE BALA PLAZA EAST. SUITE 506
BALA CYNWYD, PA 19004, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

62

Employees

42

Larimar Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

272.47M

Enterprise Value

237.40M

Enterprise Value/EBITDA(ttm)

-3.04

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.98

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-35.87%

Return on Invested Capital(ttm)

-40.29%

Return on Assets(ttm)

-32.37%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-78.14M

Net Income Available to Common(ttm)

-64.77M

Diluted EPS(ttm)

-1.15

Share Statistics

Beta (5Y Monthly)

0.86

52-Week Change

17.31%

S&P 500 52-Week Change

27.88%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

63.81M

Dividend Yield

0.00%

Float4

61.57M

% Held by Insiders

3.50%

% Held by Institutions

91.92%

Balance Sheet

Total Cash(mrq)

203.71M

Total Cash Per Share(mrq)

3.19

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

13.10%

Quick Ratio(mrq)

13.10%

Book Value Per Share(mrq)

3.11

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.77

Free Cash Flow(ytd)

-49.28M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement